Introduction

In our blog today the future Suven Pharma Share Price Target from 2024 to 2030 have been covered. By delving into extensive research and expert opinions, this article intends to give a full view of Shine Charity’s growth path, financial status on paper as well as probable market cap. So this analysis is a reference point for investors who want to learn how Suven Pharma compares to its peers in terms of profitability.

What Is Suven Pharma Company?

Suven Pharmaceuticals Limited, is a leading pharmaceutical company specializing in drug development and manufacturing incorporated on November 6, 2018. Suven Pharma: The company has a rich 33 years of experience and is considered to be one of the key players in its Industry.

Overview Of Suven Pharmaceutical Ltd Company

With headquarters in Hyderabad, Suven Pharma Inc has manufacturing sites and R&D centers across India, the USA. The company has state-of-art manufacturing facilities for different pharmaceutical products and intermediates. Publicly-listed Suven Pharma is in a merger with Cohansa Lifesciences to empower its market position.

Suven Pharma employs over 1,000 individuals, including more than 400 scientists dedicated to research. The company partners with over 25 large global firms, manufacturing semi-solids, sachets, nanotech products, and more.

Financial Data Analysis Of Suven Pharmaceutical Ltd Company

Before investing, one of the first things investors check is a company’s financial health. We analyze Suven Pharma key financial ratios here.

PE Ratio (Price To Earning Ratio)

PE Ratio is computed from the Market price per share and earnings per share. PE Ratio – 70.12 (It a not so scary also relates that Stock might be Over Valued – However, Everything happens in context of timeframes and sectors).

Return on Assets (ROA)

ROA = Profit After Tax ÷ Total Assets Suven Pharma an ROA is 13.70% means efficiency of managing assets.

Current Ratio

Current Ratio = Current Assets / Current Liabilities The current ratio of Suven Pharma is 3.64 which shows good liquidity in the Company.

Return On Equity (ROE)

ROE: Net Profit ÷ Average Shareholding Equity The ROE of Suven Pharma has been locked around 26.47%.

Suven Pharma Share Price Target 2024, 2025, 2027, 2030

Suven Pharma Shares trading uptrend. In this article, we present the future share prices targets.

Suven Pharma Share Price Target 2024

Strong growth in the pharmaceutical sector supports Suven Pharma’s strong prospects. The share price targets for 2024 are as follows;

Suven Pharma Share Price Target 2025

Continued innovation and quality assurance position Suven Pharma well for 2025. The share price targets are:

Suven Pharma Share Price Target 2027

With increasing foreign investments and market expansion, the 2027 share price targets are:

Suven Pharma Share Price Target 2030

Long-term projections indicate significant growth potential for Suven Pharma by 2030. The share price targets are:

How To Purchase Suven Pharma Share?

Investors can purchase Suven Pharma shares through common trading platforms such as:

• Zerodha
• Upstox
• Groww
• Angelone

Suven Pharmaceutical Ltd Peer’s Company

Suven Pharma’s competitors include:

• Marksans Pharma
• Orchid Pharma
• Blue Jet
• Aarti Drugs

Investors Types and Ratio of Suven Pharmaceutical Company

Advantages and Disadvantages Of Suven Pharma Share

Advantages

• Low debt levels enhance growth potential.
• Effective operating margin of 46% over the past 5 years.
• High promoter holding capacity (60%).
• Increasing FII shareholding indicates strong market confidence.

Disadvantages

• Declining profit and revenue growth over the last 3 quarters.
• Insufficient cash flow generation for sustained growth.
• High EBITDA rate of 33%.

Also Read: IRFC Share Price Target 2024, 2025, 2027, 2030

FAQ

Conclusion

Market positioning and Financial health: – Suven Pharma has been growing at a phenomenal compound annual growth of 16%. The analysis also covers projected share price targets, financial ratios and market trends. Combines and uses this information with expert advice, before taking investment decisions in Suven Pharma scrip.

Disclaimer

We are not SEBI registered advisors. Financial trading is risky. DISCLAIMERThis article is for Educational Purpose. Always consult certified experts before making any investment decisions. None of the above is to be construed as financial advice or suggestions and we are not liable for any profits that you make or losses that may occur.